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The antimalarial activity of several antiretroviral protease inhibitor combinations was investigated. Data
demonstrate that ritonavir and saquinavir behave synergistically with chloroquine and mefloquine. These data,
and interactions with pepstatin-A, E-64, and bestatin, suggest that human immunodeficiency virus protease
inhibitors do not target digestive-vacuole plasmepsins.
Although the antimalarial activity of a number of antiretro-
viral protease inhibitors (PIs; e.g., human immunodeficiency
virus [HIV] PIs) in clinical use has been established (1, 15, 20),
their mechanism of action against malaria parasites is not
known. Understanding the action of these drugs may allow the
design of a novel group of potent antimalarials. Our original
hypothesis was that, in keeping with their action as aspartyl
protease (AP) inhibitors against the HIV virus (21), these
agents interfere with a parasite AP (plasmepsin). More specif-
ically, we hypothesized that these drugs interfered with para-
site hemoglobin digestion by inhibiting one or more of the
digestive-vacuole plasmepsins. Hemoglobin digestion is essen-
tial to Plasmodium parasites by supplying amino acids for pro-
tein synthesis and development, providing space for the grow-
ing parasites, reducing the colloid-osmotic pressure of the
erythrocyte, and preventing premature cell rupture (9). Known
inhibitors of the hemoglobin digestion process with antimalar-
ial activity have been identified (2, 8) and include pepstatin A,
an AP inhibitor; E-64 [N-(trans-epoxysuccinyl)-L-leucine-4-
guanidinobutylamide], a cysteine protease inhibitor; and bestatin,
an aminopeptidase inhibitor. While the mode of chloroquine
action is still debated, it is thought to inhibit parasite growth by
preventing heme detoxification (19). In combination studies,
vacuole plasmepsin inhibitors have been shown to behave an-
tagonistically with chloroquine and mefloquine (12), while
combinations of AP inhibitors with other inhibitors of the
hemoglobin digestion process have been shown to behave syn-
ergistically (18).
Previous studies have also suggested that HIV PIs, particu-
larly ritonavir, can reduce the efflux of a drug from cells. The
synergy of mefloquine when used with HIV PIs against HIV
has been proposed to be due, at least in part, to the ability of
the HIV PIs to inhibit mefloquine efflux (14). It is unknown
whether the HIV PIs may be able to alter drug efflux in Plas-
modium falciparum, and if they can, whether this will have any
ramifications for the treatment of multidrug-resistant para-
sites. The aim of the present study was to investigate the
antimalarial activity of the HIV PI drugs saquinavir and ritona-
vir by examining their ability to inhibit the growth of P. falcip-
arum when used in combination with chloroquine, mefloquine,
pepstatin A, bestatin, or E-64.
P. falciparum clones Dd2, FAC8, and D10 were maintained
in modified candle jars as previously described (22). Antima-
larial drug combinations were assessed by isobolographic anal-
ysis (4). Assays were performed in triplicate in 96-well micro-
titer plates containing 100 l of culture (2% hematocrit and
1% parasitemia) and 100 l of drug dilutions or a control.
Parasite growth was determined based on tritiated hypoxan-
thine incorporation. Media and vehicle controls were included
on each plate. Experiments were repeated at least twice. Fifty
percent effective concentrations (EC50) (Table 1) were deter-
mined and isobolograms constructed using data from all ex-
periments. Isoboles were fitted to data using a standard hyper-
bolic function defined by the parameter I (5). Positive values of
I indicate synergism, and negative values indicate antagonism;
addition occurs when I equals 0. The significance of the dif-
ference between I and 0 was assessed with Student’s t test.
Chloroquine behaved synergistically with saquinavir and
ritonavir against the chloroquine-resistant line Dd2. I values of
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TABLE 1. EC50 of individual drugs against P. falciparum clones
during combination studies
Drug
EC50 against indicated clonea
Dd2 D10 FAC8
Chloroquine 55–85 nM NT NT
Mefloquine 60–91 nM 64–65 nM 23–33 nM
Ritonavir 0.85–6.1 M 1.1–2.8 M 7–12 M
Saquinavir 0.96–7.2 M 5.5–6.2 M NT
Pepstatin NA 14–18 M NT
E-64 2.9–6.6 M NT NT
Bestatin 5.1–14 M NT NT
a EC50 values are reported as ranges determined from all isobologram exper-












1.3 and 2.2 for saquinavir and ritonavir, respectively (Fig. 1),
were demonstrated. As was found with chloroquine, combina-
tions of mefloquine with saquinavir and ritonavir were syner-
gistic, with I values of 1.3 and 2.2, respectively (Fig. 1). The
synergistic interaction of mefloquine with ritonavir was inde-
pendent of the parasite line used. Although demonstrating the
smaller I value of 0.9, mefloquine and ritonavir also behaved
synergistically against D10 and FAC8 (Fig. 2). Combinations
of saquinavir and pepstatin were suggestive of synergy (I 
0.6), whereas combinations of saquinavir and E-64 (I  4.5)
FIG. 1. Isobolograms describing the interaction of saquinavir or ritonavir with chloroquine or mefloquine when tested against P. falciparum
isolate Dd2. The test of each combination was repeated on two occasions in triplicate. All data points are shown. FIC, fractional inhibitory
concentration.
FIG. 2. Isobolograms describing the interaction of mefloquine and ritonavir when assessed against the P. falciparum isolates D10 and FAC8.
The test of each combination was repeated on two occasions in triplicate. All data points are shown.











or saquinavir and bestatin (I  2.9) were antagonistic (Fig.
3). As Dd2 was resistant to pepstatin with an EC50 of 20 M
(Table 1), all combinations with this agent were tested with
D10. EC50 for saquinavir and ritonavir were within the range
normally achieved in humans (20). EC50 values for all drugs
are shown in Table 1.
Although a full understanding of the action of chloroquine is
lacking, evidence suggests that chloroquine kills sensitive ma-
laria parasites by preventing heme polymerization (19). Other
mechanisms of action have been suggested but are considered
less important (10). The synergistic interaction of chloroquine
with ritonavir and saquinavir suggests that these HIV PIs do
not inhibit a digestive-vacuole plasmepsin. Digestive-vacuole
plasmepsins have been shown to carry out the initial cleavage
of heme from hemoglobin (3). If this process is inhibited,
chloroquine would be prevented from accessing heme, result-
ing in antagonism, as described with other plasmepsin inhibi-
tors (12). The antagonistic action of saquinavir with E-64 and
bestatin also supports this theory. Combinations of PIs, espe-
cially those of the aspartyl and cysteine class, have been shown
to behave synergistically (18). Similar to the way that other
drug combinations inhibit sequential steps in a metabolic path-
way, it is believed that the inhibition of sequential steps in the
hemoglobin digestion pathway maximizes antimalarial activity.
Combinations of E-64 with pepstatin, a known AP inhibitor,
are reported to be synergistic (2, 18). The antagonistic nature
of the E-64 and saquinavir combination has also been sup-
ported by a recent study demonstrating that E-64 and the HIV
PI lopinavir behave antagonistically against P. falciparum (16).
The mildly synergistic nature of the pepstatin and saquinavir
combination provides additional evidence to suggest that the
HIV PIs are not targeting vacuole plasmepsins, or if they are,
that other factors are contributing to the action of these anti-
malarials. These data also support the observations of others
who have shown that when food vacuole plasmepsins are
“knocked out,” a lethal phenotype is not observed (11, 13).
Further studies will be necessary to ascertain the primary tar-
get of these drugs.
Although extrapolation of our in vitro data to the in vivo
setting should be undertaken with caution, data describing the
synergistic interactions of saquinavir and ritonavir with meflo-
quine and chloroquine are encouraging and suggest that if
chosen correctly, antimalarial and antiretroviral combinations
may be useful in the field. The results with combinations of
mefloquine with the HIV PIs suggest that these drugs may be
more effective against mefloquine-resistant parasites (Table 1;
Fig. 1 and 2), and although the use of mefloquine in areas such
as sub-Saharan Africa is likely to be restricted by cost, this
finding may hold true for other antimalarial drugs. As is true of
mefloquine, the development of malaria parasite resistance to
quinine, the artemisinin drugs, and chloroquine has been as-
sociated with drug efflux (6, 7). Although additional studies are
required to determine whether HIV PIs alter drug transport,
our data suggest that Pfmdr1 copy number is not associated
with the synergistic action of the HIV PIs with mefloquine. The
HIV PI-mefloquine combinations were more effective against
Dd2 (2 copies of Pfmdr1) than against D10 (1 copy) or FAC8
(3 copies) (17). Unless they can be shown to be effective
against chloroquine-resistant parasites, HIV PI and chloro-
quine combinations may be of limited clinical value.
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